JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB134054

Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal

4

(3 Reviews)

|

(53 Publications)

Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (ab134054) is a rabbit monoclonal antibody detecting Mu Opioid Receptor in Western Blot.

- Biophysical QC for unrivalled batch-batch consistency
- Over 40 publications

View Alternative Names

MOR1, OPRM1, Mu-type opioid receptor, M-OR-1, MOR-1, Mu opiate receptor, Mu opioid receptor, MOP, hMOP

1 Images
Western blot - Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (AB134054)
  • WB

Unknown

Western blot - Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (AB134054)

All lanes:

Western blot - Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (ab134054) at 1/1000 dilution

Lane 1:

Mu Opioid Receptor transfected HEK-293 (Human epithelial cell line from embryonic kidney) lysate at 10 µg

Lane 2:

HEK-293T cell lysate at 10 µg

Secondary

All lanes:

HRP labelled goat anti-rabbit at 1/2000 dilution

Predicted band size: 45 kDa

false

  • Carrier free

    Anti-Mu Opioid Receptor antibody [UMB3] - Low endotoxin, Azide free

  • Carrier free

    Anti-Mu Opioid Receptor antibody [UMB3] - BSA and Azide free

Key facts

Host species

Rabbit

Clonality

Monoclonal

Clone number

UMB3

Isotype

IgG

Carrier free

No

Applications

WB

applications

Immunogen

The exact immunogen used to generate this antibody is proprietary information.

Specificity

The antibody detects the band of interest in transfected cell lines. When tested in our lab, we were not able to detect any signal from the endogenous protein.
This antibody can be used in IHC and ICC/IF as demonstrated in several publications, however, it did not pass our internal validation in these applications. Please refer to PMID 20851148, 21957251, 26290245, and other references.

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"}, "WB" : {"fullname" : "Western blot", "shortname":"WB"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Mouse": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Rat": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "predicted", "WB-species-dilution-info": "", "WB-species-notes": "" }, "Recombinant fragment": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "1/100", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/rabbit-igg-monoclonal-epr25a-isotype-control-ab172730'>ab172730</a> - Rabbit monoclonal IgG, is suitable for use as an isotype control with this antibody.</p>", "WB-species-checked": "guaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>" }, "Transfected cell lysate": { "FlowCyt-species-checked": "notRecommended", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "", "WB-species-checked": "testedAndGuaranteed", "WB-species-dilution-info": "1/1000 - 1/10000", "WB-species-notes": "<p></p>" } } }

Product details

What is this antibody validated in?
Anti-Mu Opioid Receptor antibody [UMB3] - C-terminal (ab134054) is a rabbit recombinant monoclonal antibody and is validated for use in Western Blot (WB). What is the molecular weight of Mu Opioid Receptor?
Anti-Mu Opioid Receptor [UMB3] - C-terminal (ab134054) specifically detects a band for Mu Opioid Receptor (UniProt: P35372) at a molecular weight of 45kDa.

Trusted by the scientific community
Anti-Mu Opioid Receptor [UMB3] - C-terminal (ab134054) was first used in a scientific publication in 2012 and has been cited over 40 times in peer-reviewed journals.

Trial sizes available!
Test your antibody or perform pre-screening before committing to a larger quantity. Sold in 10µl. Discover our selection of trial-size antibodies.

Other related products
We have a range of other formats of antibody clone [UMB3] also available for your convenience: ab134054, Carrier free - ab227067, Carrier free - ab271900

Patented technology
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein A
Storage buffer
pH: 7.2 - 7.4 Preservative: 0.01% Sodium azide Constituents: PBS, 40% Glycerol (glycerin, glycerine), 0.5% BSA
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Storage information
Stable for 12 months at -20°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The Mu Opioid Receptor also known as MOR mu receptor or mu opiate receptor represents an important protein involved in pain and reward mechanisms. It is a G-protein coupled receptor with a mass of approximately 45 kDa. This receptor shows broad expression in the central nervous system with significant presence in areas such as the brainstem thalamus and spinal cord. MORs have a high affinity for endogenous opioids such as endorphins as well as exogenous opioid drugs like morphine.
Biological function summary

The Mu Opioid Receptor plays an essential role in modulating pain perception and response to opioids. It interacts predominantly with inhibitory G-proteins reducing neuronal excitability by decreasing cAMP levels and increasing potassium ion conductance. MORs are part of opioid receptor family which also includes delta and kappa receptors forming a complex regulatory system for the opioid signaling pathways. These receptors also modulate the release of neurotransmitters like GABA and dopamine.

Pathways

Signaling through the Mu Opioid Receptor integrates with the analgesic and reward pathways. It is important in the pain modulation pathway where it influences the perception of and response to pain stimuli. MORs interact with proteins such as adenylate cyclase and beta-arrestin which mediate desensitization and down-regulation processes. This interaction can also modulate the activity of dopamine pathways further linking MOR to reward and addiction mechanisms.

The Mu Opioid Receptor is closely connected to conditions like addiction and chronic pain. Anomalies in MOR function or expression can lead to an increased risk of opioid addiction due to its pivotal role in the reward pathway. Additionally chronic pain conditions might involve altered MOR signaling or density impacting pain management. Understanding MOR interactions with proteins like dopamine receptors can provide deeper insights into Huntington's disease and the role of opioid receptors in its pathology.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Receptor for endogenous opioids such as beta-endorphin and endomorphin (PubMed : 10529478, PubMed : 12589820, PubMed : 7891175, PubMed : 7905839, PubMed : 7957926, PubMed : 9689128). Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone (PubMed : 10529478, PubMed : 10836142, PubMed : 12589820, PubMed : 19300905, PubMed : 7891175, PubMed : 7905839, PubMed : 7957926, PubMed : 9689128). Also activated by enkephalin peptides, such as Met-enkephalin or Met-enkephalin-Arg-Phe, with higher affinity for Met-enkephalin-Arg-Phe (By similarity). Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors (PubMed : 7905839). The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1 isoforms Alpha-1 and Alpha-2, and to a lesser extent to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15 (PubMed : 12068084). They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B (By similarity). Also couples to adenylate cyclase stimulatory G alpha proteins (By similarity). The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4 (By similarity). Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization (By similarity). Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction (By similarity). The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins (By similarity). The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation (By similarity). Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling (By similarity). Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling (By similarity). Endogenous ligands induce rapid desensitization, endocytosis and recycling (By similarity). Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties (By similarity).. Isoform 12. Couples to GNAS and is proposed to be involved in excitatory effects.. Isoform 16. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.. Isoform 17. Does not bind agonists but may act through oligomerization with binding-competent OPRM1 isoforms and reduce their ligand binding activity.
See full target information OPRM1

Publications (53)

Recent publications for all applications. Explore the full list and refine your search

Alzheimer's research & therapy 17:35 PubMed39893485

2025

Delta-opioid receptor signaling alleviates neuropathology and cognitive impairment in the mouse model of Alzheimer's disease by regulating microglia homeostasis and inhibiting HMGB1 pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Yuan Xu,Naiyuan Shao,Feng Zhi,Ronghua Chen,Yilin Yang,Jiahui Li,Ying Xia,Ya Peng

The Journal of comparative neurology 532:e70003 PubMed39656141

2024

Developmental and Adult Striatal Patterning of Nociceptin Ligand Marks Striosomal Population With Direct Dopamine Projections.

Applications

Unspecified application

Species

Unspecified reactive species

Emily Hueske,Carrie Stine,Tomoko Yoshida,Jill R Crittenden,Akshay Gupta,Joseph C Johnson,Ananya S Achanta,Smitha Bhagavatula,Johnny Loftus,Ara Mahar,Dan Hu,Jesus Azocar,Ryan J Gray,Michael R Bruchas,Ann M Graybiel

Nature communications 15:8856 PubMed39402067

2024

Dopamine release plateau and outcome signals in dorsal striatum contrast with classic reinforcement learning formulations.

Applications

Unspecified application

Species

Unspecified reactive species

Min Jung Kim,Daniel J Gibson,Dan Hu,Tomoko Yoshida,Emily Hueske,Ayano Matsushima,Ara Mahar,Cynthia J Schofield,Patlapa Sompolpong,Kathy T Tran,Lin Tian,Ann M Graybiel

BMC gastroenterology 24:23 PubMed38191294

2024

The P2Y receptor in the colonic myenteric plexus of rats and its correlation with opioid-induced constipation.

Applications

Unspecified application

Species

Unspecified reactive species

Yuqiong Zhao,Huijuan Luo,Xiaojie Ren,Binghan Jia,Jinzhao Li,Lixin Wang,Junping Li

The Journal of neuroscience : the official journal of the Society for Neuroscience 44: PubMed38124021

2023

Opioid-Induced Hyperalgesia and Tolerance Are Driven by HCN Ion Channels.

Applications

Unspecified application

Species

Unspecified reactive species

Xue Han,Larissa Garcia Pinto,Bruno Vilar,Peter A McNaughton

Current biology : CB 33:5011-5022.e6 PubMed37879332

2023

Striatopallidal cannabinoid type-1 receptors mediate amphetamine-induced sensitization.

Applications

Unspecified application

Species

Unspecified reactive species

Yamuna Mariani,Ana Covelo,Rui S Rodrigues,Francisca Julio-Kalajzić,Antonio C Pagano Zottola,Gianluca Lavanco,Michela Fabrizio,Doriane Gisquet,Filippo Drago,Astrid Cannich,Jerome Baufreton,Giovanni Marsicano,Luigi Bellocchio

Biosensors & bioelectronics 241:115625 PubMed37708685

2023

Scalable, flexible carbon fiber electrode thread arrays for three-dimensional probing of neurochemical activity in deep brain structures of rodents.

Applications

Unspecified application

Species

Unspecified reactive species

Mingyi Xia,Busra Nur Agca,Tomoko Yoshida,Jiwon Choi,Usamma Amjad,Kade Bose,Nikol Keren,Shahar Zukerman,Michael J Cima,Ann M Graybiel,Helen N Schwerdt

Nature communications 14:5632 PubMed37704594

2023

Human OPRM1 and murine Oprm1 promoter driven viral constructs for genetic access to μ-opioidergic cell types.

Applications

Unspecified application

Species

Unspecified reactive species

Gregory J Salimando,Sébastien Tremblay,Blake A Kimmey,Jia Li,Sophie A Rogers,Jessica A Wojick,Nora M McCall,Lisa M Wooldridge,Amrith Rodrigues,Tito Borner,Kristin L Gardiner,Selwyn S Jayakar,Ilyas Singeç,Clifford J Woolf,Matthew R Hayes,Bart C De Jonghe,F Christian Bennett,Mariko L Bennett,Julie A Blendy,Michael L Platt,Kate Townsend Creasy,William R Renthal,Charu Ramakrishnan,Karl Deisseroth,Gregory Corder

Frontiers in molecular neuroscience 16:1207911 PubMed37389091

2023

Lactobacillus rhamnosus GG and butyrate supplementation in rats with bone cancer reduces mechanical allodynia and increases expression of μ-opioid receptor in the spinal cord.

Applications

Unspecified application

Species

Unspecified reactive species

Wenxi Yuan,Jie Xiao,Huabao Liao,Zhiyuan Xie,Yiran Zhao,Cheng Li,Keying Zhou,Xue-Jun Song

Communications biology 6:419 PubMed37061609

2023

In situ visualization of opioid and cannabinoid drug effects using phosphosite-specific GPCR antibodies.

Applications

Unspecified application

Species

Unspecified reactive species

Sebastian Fritzwanker,Falko Nagel,Andrea Kliewer,Viviane Stammer,Stefan Schulz
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com